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Commentary
Killing the umpire: cooperative defects in mitotic checkpoint and
BRCA2 genes on the road to transformation
Frank McKeon
Harvard Medical School, Boston, Massachusetts, USA
Abstract
Recent findings from mouse models of BRCA2 genetic lesions have provided intriguing
insights and important questions concerning modes of tumor development in familial
breast and ovarian cancers. Fibroblasts from mice homozygous for the BRCA2Tr allele grow
poorly and display an array of chromosomal abnormalities that are consistent with a role for
BRCA2 in DNA repair. This growth defect can be overcome and cellular transformation
promoted by the expression of defective, dominant negative alleles of p53 and of the
mitotic checkpoint gene Bub1, both of which are known to induce chromosome instability.
These findings are mirrored in the genetic lesions sustained in tumors found in the rare
BRCA2Tr/Tr mice that survive to adulthood, which include defects in p53 as well as the
mitotic checkpoint proteins Bub1 and Mad3L. Together, these data hint that tumors in
these mice evolve from an unusually intense selective pressure to remove DNA damage
checkpoints, which in turn might be facilitated by chromosomal abolition of mitotic
checkpoints and the consequent increase in shuffling of genetic information. How these
genetic lesions co-operate to yield transformed cells and how these data relate to BRCA1
and BRCA2 defects in the human population are important questions raised by this work.
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Introduction
The BRCA1 and BRCA2 genes have attracted intense
interest because their mutations have been tightly linked
to inherited forms of breast and ovarian cancers, which
comprise fully 20% of all cases of these malignancies [1].
Linkage analysis and positional cloning of the BRCA
genes from affected families provided a rare glimpse into
proteins whose malfunction leads to particular cancers and
myriad biologic questions concerning underlying mecha-
nisms. Understanding how these proteins function in the
cell and why mutations predispose individuals to an often
early onset of breast and ovarian cancers are considered
essential milestones in efforts to mitigate these diseases. 
Both  BRCA1, located at 17q21, and BRCA2, located at
13q12-13, encode large proteins (1863 and 3418 amino
acids, respectively), and are often colocalized during
embryonic development to proliferating cell populations
undergoing differentiation. This observation, together
with molecular analyses of interaction proteins, suggest
that BRCA1 and BRCA2 act in a complex with other cel-
lular proteins, including the DNA repair protein Rad51, to
monitor, signal, and correct genetic damage [2].
Murine models for BRCA1 and BRCA2 mutations have
been stifled by the lack of phenotypes in the heterozy-
gotes, and the early embryonic lethality of mice lacking
both copies of BRCA1 or BRCA2 [3,4]. Considering the
large number of DNA repair events required for genome
duplication during a normal cell cycle, it may not be sur-
prising that the loss of either of these genes would disrupt
normal development. Significantly, both p53 and p21 arehttp://breast-cancer-research.com/vol1no1/07oct99/dispatch/3
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highly expressed in BRCA1- and BRCA2-deficient
embryos, suggesting that these DNA damage checkpoint
responses are intact and probably contribute to the
arrested development phenotype of these mutant
embryos. Indeed, the coincident loss of p53 permits some-
what extended progression of BRCA1–/– and BRCA2–/–
embryos, suggesting that p53, as well as other checkpoint
proteins, are activated in these mice to induce cell cycle
arrest to allow for repair processes [4].
In an effort to generate viable mouse models for BRAC2
defects, more discrete lesions in the BRCA2 gene were
produced that result in C-terminal truncations of the
protein that corresponds to certain human germline BRCA2
mutations [5]. Interestingly, some of these BRCA2Tr/Tr mice
survive embryonic development to reach adulthood, albeit
with numerous anomalies in somatic growth, poor differen-
tiation of selected tissues, and eventually thymic lym-
phomas. As with the more complete loss-of-function
BRCA2 mutants, fibroblasts from the BRCA2Tr/Tr embryos
show poor growth kinetics and high levels of p53 and p21.
In addition, these fibroblasts grow more slowly with suc-
cessive passages and accumulate increasing numbers of
chromosomal abnormalities [5]. Thus, it is likely that the
unrepaired DNA damage in the BRCA2Tr/Tr cells triggers
checkpoints that in turn hinder cell proliferation.
It was this seeming paradox – a mutant tumor suppressor
causing cell cycle arrest rather than permitting unbridled pro-
liferation – which held the attention of Venkitaraman and
coworkers [6], who set out to reconcile these data with the
known association of BRCA2 mutations in early onset breast
and ovarian cancers [1]. The result of this work was the
intriguing discovery that the growth defects of cells harboring
the BRCA2Tr/Tr alleles could be overcome in a manner to
promote transformation by the loss of p53 or the mitotic
checkpoint gene Bub1. Defects in these genes either directly
relieve the checkpoints that monitor the abnormal
BRCA2Tr/Tr chromosome structure or accelerate chromosomal
aneuploidy leading to loss or gain of genetic elements that
co-operate with BRCA2 defects in transformation.
Mutant p53 and dominant-negative Bub1:
acting in same pathway?
Probably no image is more telling of the defect in the
BRCA2Tr/Tr cell lines than the mitotic chromosome spreads
showing multiple breaks and alterations, presumably due to
repair defects and mitotic recombination events [6]. Such
events are likely to trigger the observed elevations in p53,
and may also promote mitotic checkpoint genes, which
ensure proper chromosome alignment and segregation.
Lee et al [6] tested this notion by expressing dominant-neg-
ative versions of p53 and Bub1 (N-Bub1) in the BRCA2Tr/Tr
fibroblasts. Significantly, two mutant p53 alleles and a dom-
inant-negative Bub1 construct rescued the proliferation
defect in the BRCA2Tr/Tr cells, presumably by suppressing
various checkpoints that monitor abnormal chromosome
structure or segregation. The authors therefore expected
that these growth-rescued cells would now be unleashed to
allow even more aberrantly structured chromosomes. The
N-Bub1 and the p53R273L expressing cells, although ane-
uploid, were surprisingly devoid of abnormal chromosomes.
This was not the case for cells that expressed the other p53
allele, G154V, which also rescued the growth defect, but
cells retained the abnormal chromosome structures. These
intriguing results indicate several mechanisms by which
mutations in checkpoint genes could cooperate with
BRCA2 mutations to promote aggressive cell growth.
The continued growth of BRCA2Tr/Tr cells that express the
p53 G154V mutant may be more easy to grasp as p53 acts to
sense DNA damage and monitor repair, and its absence via
mutation or suppression is common to many transformed
cells. The apparent lack of chromosomal abnormalities in
the cells expressing p53R273L or N-Bub1 is more difficult
to comprehend. It is known, for instance, in the absence of
p53 or by suppressing Bub1 activity via dominant-negative
Bub1, cells avoid cell cycle arrest and apoptosis normally
associated with the absence of chromosome alignment in
mitosis [7,8]. Whereas these actions might explain the
rescue of the growth inhibition of the BRCA2Tr/Tr cells by
p53R273L or N-Bub1, they fail to illuminate why the
rescued cells lack chromosomal abnormalities.
Several possible mechanisms are certainly under considera-
tion by researchers. One would have to posit that the abnor-
mal chromosome structures observed in the BRCA2Tr/Tr cells
are in fact reflections of failed repair processes, and that the
assembly of the repair complexes onto chromosomes is
somehow dependent on particular cell cycle arrest states
mediated by p53 or components of the mitotic checkpoint.
It would follow that these ‘rescued’ cells have as much DNA
damage but appear normal due to the lack of repair interme-
diates. The second possibility is that the p53R273L and N-
Bub1 mutants allow cells to bypass critical apoptotic events
and therefore create a large population of cells from which
those with the least chromosomal abnormalities are selected.
Although undoubtedly an area of intense research interest,
this conundrum led Lee et al [6] to examine the thymic
lymphomas arising in the BRCA2Tr/Tr mice for chromoso-
mal abnormalities. Remarkably, cells from these tumors
were free of significant chromosomal defects, suggesting a
similar loss in checkpoint activities as seen in the
BRCA2Tr/Tr fibroblasts that express p53R273L or N-Bub1.
Analysis of the small sample of tumors available (only 1 in
100 of the BRCA2Tr/Tr mice survive to adulthood) revealed
that all had defects in p53, Bub1, or the Bub1-related gene
Mad3L. Curiously, three of the lymphomas showed a
similar spectrum of genetic defects involving unusual het-
erozygous deletions of a region around amino acidsBreast Cancer Research    Vol 1 No 1 McKeon
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140–148 of the p53 gene, as well as identical, in-frame
deletion/insertions in the Bub1 gene substituting M290
with codons encoding isoleucine and arginine. A fourth
lymphoma showed a heterozygous mutation in the Mad3L
gene and lacked obvious changes in p53 or Bub1. Interest-
ingly, all of the p53, Bub1, and Mad3L mutants func-
tioned as dominant-negative agents in cells with regard to
the mitotic checkpoint, suggesting that the lymphoma
cells are defective in these functions despite the presence
of a single wild-type gene.
The work of Lee et al [6] has implications for mechanisms
of cell transformation in general and tumorigenesis involv-
ing BRCA2 mutations in particular. For one, it is the
second indication, following that of Cahill et al [9], that
mutations in mitotic checkpoint regulators participate in
the genomic instability thought to promote tumorigenesis.
In the latter case, mutations in Bub1 and Mad3L (BubR1)
were found in colorectal carcinoma cell lines displaying a
particular genomic instability marked by rapid loss and
gains of entire chromosomes (chromosome instability) [9].
It should be noted here that analyses of the Bub1 gene in
head and neck squamous cell carcinomas, typically aneu-
ploid tumors, failed to detect mutations [10]. Moreover,
Cahill et al [9] found that only several of the colorectal
carcinoma cell lines displaying the chromosome instability
phenotype showed mutations in the Bub1 or Mad3L
genes. It is likely that many, yet to be discovered genes
play critical roles in the various checkpoint pathways that
govern accurate chromosome segregation, and mutations
in such genes could contribute to the genetic instability
that promotes tumor cell evolution.
Conclusion
With regard to tumor development in cells that harbor
BRCA2 mutations, the findings of Lee et al [6] are sure to
stimulate much discussion and many new experiments.
The data are increasing that breast and ovarian tumors that
arise in individuals who harbor BRCA1 or BRCA2 muta-
tions show frequent and unusual p53 genetic defects, sug-
gesting particular pathways of tumor development in these
patients [11,12]. In this regard, the intriguing models pre-
sented by Lee et al indicate that cells homozygous for the
BRCA2Tr allele almost require checkpoint defects in order
to merely proliferate, therefore providing additional selec-
tive pressure to remove checkpoint mechanisms by genetic
lesions. Given that such alterations in p53, together with
those in genes that are thought to specifically govern
mitotic chromosome alignment, rescue the growth defects
in BRCA2Tr/Tr cells, the end product has both poor DNA
repair capabilities but no failsafe mechanisms to deter their
continued propagation. These cells might therefore be
expected to evolve rapidly through chromosome aneu-
ploidy and an unbridled accumulation of mutations, which
together would yield a dangerous brew of progeny upon
which growth selection operates.
The issue of cooperating mutations coinciding with
BRCA1 and BRCA2 lesions brings forth another interest-
ing observation from the paper by Lee et al [6] concerning
p53 and mitotic checkpoint mutations. Although not
tested directly, evidence is mounting that p53, in addition
to its other well established functions, mediates the cell
cycle arrest and apoptosis that follows the activation of the
mitotic checkpoint. It is therefore curious that most of the
thymic lymphomas of the BRCA2Tr/Tr mice showed muta-
tions both in p53 and Bub1, suggesting some additional
advantage for the loss of both activities. Obviously this
result suggests a more complex story than Bub1 activating
p53 to guard against aneuploidy, but then again the intri-
cacies of mechanisms that ensure chromosome segregation
have only recently been addressed. Whereas p53 muta-
tions are more frequent in BRCA1 and BRCA2 tumors than
in sporadic cases of breast cancer, it will of significant
interest to determine whether mutations in mitotic check-
point proteins, including Bub1, Bub3, Mad1, Mad2, and
Mad3L, contribute to the progression of human BRCA1
and BRCA2 tumors [13]. It is certain that such analyses
will yield additional surprises that impact both on the
biology of mitosis and on the pathology of cancer cells.
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